A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Principal Investigator
Patrick Flynn, MD
Status
Temporarily Closed to Accrual & Treatment
Date Opened To Accrual
April 04 2012
Date Closed to Accrual
November 21 2013
Disease Site
Breast [BR]
Breast
Phase
III
Developmental Therapeutics
No
Primary Objective
To determine if the TC regimen is non-inferior to the anthracycline-based chemotherapy regimens in terms of invasive disease-free survival (IDFS) by combining B-49 data with the TAC and TC arms of NSABP B-46-I/USOR 07132 and the data from USOR 06-090.
Patient Population
Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Target Accrual
1843
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.